The Power of the Purse: FDA Seeks More Money, Not More Authority

Congress can't wait to shower FDA with more regulatory authority, especially in the area of drug safety. But unless Capitol Hill can puts its money where its mouth is, expanding FDA's mission will only send the agency deeper into a fiscal crisis -- and leave industry worse off as a result. An underfunded agency leaves officials scrambling to complete day-to-day activities -- and less time to on activities to further drug development, like nanotechnology and the Critical Path initiative.

More from Clinical Trials

More from R&D